Diamyd Medical will receive USD 1.75 million in expanded collaboration support from Breakthrough T1D (formerly JDRF), the world's leading Type 1 Diabetes ...

REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside ...

Questions properties, and in multiple disease areas. Ultimovacs and the shareholders of Zelluna Immunotherapy AS have entered into a definitive business combination agreement to combine the two ...

Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company was formerly known as Epicure Charcoal, Inc. and changed its name ...

Medicare covers immunotherapy treatment for cancer. Out-of-pocket costs will vary, depending on the Medicare plan a person has and whether or not they have supplemental insurance. If a person has ...

This is used to develop and provide you with services, content, commercial offers, and advertisements across your various devices and screens (including by email, mail, texts, phone, audio, and video) ...

(RTTNews) - INmune Bio, Inc. (INMB), a clinical-stage biotechnology company focused on immunotherapy treatments, announced Tuesday the expansion of its ongoing Phase I/II trial to include veterans ...

“Immunotherapy in the MSI-high subset of patients continues to amaze us, and it is holding true with these combination therapies even more,” he continued. With encouraging results, this combination ...

Messenger RNA (mRNA) vaccines offer an adaptable and scalable platform for cancer immunotherapy, requiring optimal design to elicit a robust and targeted immune response. Recent advancements in ...